Serum IL-17F as a biomarker of infection-independent cirrhosis progression
IL-17F expression declines progressively with increasing severity of liver disease, independently of IL-17A. These findings support a distinct, possibly immunoregulatory role for IL-17F in cirrhosis progression, and warrant further mechanistic investigation into its functional relevance as a biomarker for disease stratification or as a therapeutic target.
Authors
- Andreas Schütte (ORCID: https://orcid.org/0000-0002-9915-0601)
- Sabrina Guckenbiehl
- Moritz Passenberg (ORCID: https://orcid.org/0009-0001-7235-7338)
- Hartmut Hans-Jürgen Schmidt (ORCID: https://orcid.org/0000-0002-2402-7764)
- Bill Jung
- Jassin Rashidi‐Alavijeh (ORCID: https://orcid.org/0000-0001-8216-0064)
- Nargiz Nuruzade
- Dieter P. Hoyer (ORCID: https://orcid.org/0000-0001-6206-7559)
- Georgios Konstantis (ORCID: https://orcid.org/0000-0002-1031-6418)
- Katharina Willuweit (ORCID: https://orcid.org/0000-0002-1474-7733)
- Jan Best (ORCID: https://orcid.org/0000-0003-2074-0930)
- Florian Seltsam
- Clara Guntlisbergen
Institutions
- Essen University Hospital (DE)
- University of Duisburg-Essen (DE)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-22
- DOI
- https://doi.org/10.3389/fimmu.2025.1671288
- Citations
- 1
- Primary Topic
- Liver Disease and Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 1.32
Funders
- Universität Duisburg-Essen